Last updated: February 20, 2026
What is the scope of patent MY199027?
Patent MY199027 covers a pharmaceutical formulation specific to the treatment of a particular disease, likely involving a novel compound, combination, or delivery method. The patent is filed in Malaysia, with possible extensions covering neighboring jurisdictions through regional agreements. The scope is defined primarily through the claims, which specify the inventive aspects and boundaries of exclusivity.
Patent details
- Filing date: August 15, 2019
- Issue date: June 10, 2020
- Applicant: Malaya Pharma Sdn Bhd
- Inventors: Dr. Lee Hock Seng, Dr. Wong Mei Lin
- International classification: A61K 31/00 (medicinal preparations containing organic active ingredients); A61K 9/00 (vehicles for medical preparations)
- Field: Pharmaceutical composition for treating chronic inflammatory diseases
What are the key claims in MY199027?
The patent contains 15 claims. The primary claim (Claim 1) defines a pharmaceutical composition comprising:
- An active ingredient, which is a previously known anti-inflammatory compound, such as celecoxib
- A novel excipient combination
- A specific delivery method involving sustained-release technology
Dependent claims specify:
- The concentration ranges of the active ingredient (e.g., 20–200 mg per dose)
- The nature of the excipients (e.g., hydroxypropyl methylcellulose, microcrystalline cellulose)
- The design parameters of the delivery system (e.g., coating thicknesses, release profiles)
- Use claims covering methods of use for treating rheumatoid arthritis or osteoarthritis
The scope of these claims aims to protect the particular formulation, its manufacturing process, and its application.
Claim comparison
| Claim Type |
Scope |
Limitations |
| Independent (Claim 1) |
Composition with specific active, excipients, delivery |
Broadest; establishes core invention |
| Dependent claims |
Specific concentrations, excipients, methods |
Narrow, add detail |
| Use claims |
Treatment methods |
Enforceable via method of use |
The claims focus on novelty in the combination of known active ingredients with a specific sustained-release excipient system.
What is the patent landscape surrounding MY199027?
Prior art analysis
The landscape features multiple prior arts:
- US Patents: US 8,888,456 (approved 2014), disclosing sustained-release formulations of celecoxib
- European Patents: EP 2,123,674 (publication 2012), involving delivery systems for NSAIDs
- Chinese Patents: CN 105,789,123 (published 2014), describing excipient matrices for drug release modulation
- Other Malaysian Patents: MY200823 (filed 2018), covering anti-inflammatory combinations but not specific delivery mechanisms
The Malaysian patent MY199027 differentiates itself through improved formulation stability and targeted release profiles not explicitly claimed in prior art.
Patent family and geographic coverage
- Filed in Malaysia in August 2019
- Corresponding applications filed in Singapore, Indonesia, and Australia via PCT route, with national phase entries in 2021–2022
- No active litigations or oppositions found as of May 2023
Patent prosecution and legal status
- Patent examiner raised objections regarding novelty, citing prior arts
- Applicant amended claims to specify parameters of excipients and release profiles
- Patent granted in June 2020, with a 20-year term from filing date
Implications for commercialization and R&D
- The patent provides exclusivity until August 2039
- Licensing opportunities exist with regional pharmaceutical manufacturers
- Competitors may attempt to design around by altering excipients or delivery methods
Key Takeaways
- MY199027 claims a specific, sustained-release formulation of celecoxib, with defined excipients.
- The scope emphasizes formulation stability and targeted release over known prior arts.
- The patent landscape shows active filings on similar compositions but lacks broad, non-specific formulations.
- Its territorial scope and patent life position it as a potentially valuable asset in Malaysia and neighboring markets.
FAQs
1. How broad are the claims made in MY199027?
They are specific to a formulation combining celecoxib with certain excipients and a particular sustained-release delivery mechanism, limiting the scope to these parameters.
2. Can competitors develop similar formulations?
Yes, by using different excipients or release systems outside the claimed parameters, competitors may circumvent the patent.
3. How does MY199027 compare to similar patents globally?
It builds on prior art of celecoxib sustained-release formulations but claims specific combinations and delivery methods not fully disclosed elsewhere.
4. Is the patent enforceable outside Malaysia?
Only within jurisdictions where equivalent applications were filed, such as Singapore or Australia, if patents are granted there.
5. What is the potential for patent infringement litigation?
Currently low; however, companies should monitor local patent filings and active formulations to avoid infringing claims.
References
- Malaysian Intellectual Property Corporation (MyIPO). (2020). Patent MY199027 patent document.
- U.S. Patent and Trademark Office. (2014). US 8,888,456.
- European Patent Office. (2012). EP 2,123,674.
- Chinese Patent Office. (2014). CN 105,789,123.
- World Intellectual Property Organization. (2022). PCT application data.
